Elite Pharmaceuticals, Inc.
ELTP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $36,322 | $40,211 | $31,996 | $14,364 |
| % Growth | -9.7% | 25.7% | 122.7% | – |
| Cost of Goods Sold | $22,249 | $12,985 | $14,701 | $8,245 |
| Gross Profit | $14,073 | $27,226 | $17,295 | $6,119 |
| % Margin | 38.7% | 67.7% | 54.1% | 42.6% |
| R&D Expenses | $1,385 | $1,675 | $2,041 | $1,794 |
| G&A Expenses | $4,029 | $3,456 | $2,087 | $2,725 |
| SG&A Expenses | $4,029 | $3,456 | $2,087 | $2,725 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $445 | $395 | $2,013 | $503 |
| Operating Expenses | $5,859 | $5,526 | $6,141 | $5,022 |
| Operating Income | $8,214 | $21,700 | $11,154 | $1,098 |
| % Margin | 22.6% | 54% | 34.9% | 7.6% |
| Other Income/Exp. Net | $7,477 | -$22,264 | $8,118 | -$11,751 |
| Pre-Tax Income | $15,690 | -$564 | $19,272 | -$10,653 |
| Tax Expense | $1,988 | $5,321 | $2,274 | $239 |
| Net Income | $13,702 | -$5,885 | $16,998 | -$10,892 |
| % Margin | 37.7% | -14.6% | 53.1% | -75.8% |
| EPS | 0.01 | -0.006 | 0.016 | -0.01 |
| % Growth | 281.8% | -134.6% | 255.9% | – |
| EPS Diluted | 0.01 | -0.006 | 0.016 | -0.01 |
| Weighted Avg Shares Out | 1,071,897 | 1,068,363 | 1,068,363 | 1,068,273 |
| Weighted Avg Shares Out Dil | 1,141,536 | 1,068,363 | 1,068,363 | 1,068,273 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $5 | $5 | $5 |
| Interest Expense | $82 | $159 | $189 | $78 |
| Depreciation & Amortization | $395 | $508 | $520 | $490 |
| EBITDA | $16,168 | $103 | $19,981 | -$10,086 |
| % Margin | 44.5% | 0.3% | 62.4% | -70.2% |